FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF

Title:

FUSION PROTEIN COMPRISING ANTI-LAG-3 ANTIBODY AND IL-2, AND USE THEREOF

Document Type and Number:

WIPO Patent Application WO/2022/005174

Kind Code:

A1

Abstract:

The present invention relates to a fusion protein comprising an anti-LAG-3 antibody and IL-2 or a variant thereof. In the fusion protein of the present invention, the anti-LAG-3 antibody portion binds to LAG-3 to control the bond between LAG-3 and MHCⅡ. Also, IL-2 protein or a variant thereof can control the activity of T cells. Therefore, a pharmaceutical composition comprising the fusion protein increases the immune activity in the body and thus can be used as an anticancer drug and is highly likely to be utilized on an industrial scale.

More Like This:

WO/2013/004185	BROADLY CROSS-REACTIVE HIV-1-SPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV
JP7386382	Chimeric antigen receptors and T cell receptors and methods of use
WO/2004/101616	LIVER X RECEPTOR &agr SPLICING MUTANT PROTEIN, GENE THEREOF AND UTILIZATION OF THE SAME

Inventors:

JANG MYOUNG HO (KR)
CHO YOUNG-GYU (KR)
OH YOUNG MIN (KR)
LEE HYE SUN (KR)
HA DAN BEE (KR)
SHIM YAEIN (KR)
KIM SEOHO (KR)

Application Number:

PCT/KR2021/008198

Publication Date:

January 06, 2022

Filing Date:

June 29, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

GI INNOVATION INC (KR)

International Classes:

C07K16/28; A61K38/00; A61K39/00; A61P35/00; C07K14/55

Domestic Patent References:

WO2019191295A1	2019-10-03
WO2020113403A1	2020-06-11

Foreign References:

KR20190032355A	2019-03-27
KR20200002678A	2020-01-08
US5229109A	1993-07-20
KR101667096B1	2016-10-18

Other References:

MATTHEW KRAMAN, MUSTAPHA FAROUDI, NATALIE L. ALLEN, KATARZYNA KMIECIK, DANIEL GLIDDON, CLAIRE SEAL, ALEXANDER KOERS, MATEUSZ M. WY: "FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity", CLINICAL CANCER RESEARCH, vol. 26, no. 13, 1 July 2020 (2020-07-01), US, pages 3333 - 3344, XP055722366, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-19-3548
IMAI ET AL., CANCER SCI, vol. 98, 2007, pages 416 - 423
ENGELSUHLMANN, ANGEW CHEM INT ED ENGL., vol. 37, 1988, pages 73 - 127
GILLIES ET AL., J. IMMUNOL. METH, vol. 125, 1989, pages 191 - 202
SAKANO ET AL., NATURE, vol. 286, 1980, pages 676 - 683
WATSON ET AL., NUCLEIC ACID RESEARCH, vol. 12, 1984, pages 5145 - 5164
"Remington's Pharmaceutical Sciences", 1995
See also references of EP 4174088A4

Attorney, Agent or Firm:

RYU, Jong Woo et al. (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: BASE STATION DEVICE AND METHOD FOR OPERATING BASE STATION DEVICE

Next Patent: METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME